First patients to test experimental cancer drug FP008
NCT ID NCT06990698
Summary
This is the first time researchers are testing the experimental drug FP008 in people with advanced solid tumors. The study aims to find a safe dose and see how the body processes the drug. It will also check if the drug shows any early signs of helping control cancer in patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.